Suppr超能文献

乳腺癌转移抑制因子-1(BRMS-1)在人乳腺癌中的表达及其对乳腺癌细胞迁移的生物学影响。

Expression of breast cancer metastasis suppressor-1, BRMS-1, in human breast cancer and the biological impact of BRMS-1 on the migration of breast cancer cells.

机构信息

Metastasis and Angiogenesis Research Group, CUPUCI, Cardiff University School of Medicine, Henry Welcome Building, Heath Park, Cardiff CF14 4XN, U.K.

出版信息

Anticancer Res. 2014 Mar;34(3):1417-26.

Abstract

UNLABELLED

Breast cancer metastasis suppressor-1 (BRMS1) is a candidate metastasis-suppressing gene and has been shown to potentially inhibit tumor progression without blocking the growth of orthotopic tumors, in different tumor types including non-small cell lung cancer, ovarian, melanoma and breast cancers.

MATERIALS AND METHODS

BRMS-1 gene transcript was quantified in breast cancer sample tissues and analyzed against histological and clinical patient outcome. Human breast cancer cell lines, MDA MB-231 and MCF-7 were used to genetically-modify the expression of BRMS-1 and test for biological responses following BRMS-1 modifications. Key candidate signal pathways, influenced by BRMS-1 were also explored.

RESULTS

BRMS1 was present in MDA MB-231 and MCF-7 cell lines. Using anti-BRMS1 transgenes, we knocked-down the transcripts of BRMS1 in both cells at the mRNA and protein levels. Knockdown of BRMS1 gave both cells a faster cell growth rate, rapid pace of cellular migration and invasion, compared to respective wild-type and control cells (p<0.05). Blocking phospholipase-Cγ (PLCγ) had a significant influence on the BRMS-1-induced cell migration. Finally, significantly low levels of BRMS1 were observed in patients with high-grade tumors (p=0.12), in patients with distant metastasis (p=0.05) and those who died of breast cancer (p=0.0037). In addition, patients with low levels of BRMS1 had a significantly shorter overall survival (p=0.035).

CONCLUSION

BRMS-1 is aberrantly expressed in human breast cancer and is inversely-correlated with disease progression and patient survival. This is likely to be occurring via its influence on invasion and migration of breast cancer cells.

摘要

未加标签

乳腺癌转移抑制因子-1(BRMS1)是候选转移抑制基因,已显示出在不同肿瘤类型中,包括非小细胞肺癌、卵巢癌、黑色素瘤和乳腺癌中,具有抑制肿瘤进展而不阻止原位肿瘤生长的潜力。

材料和方法

在乳腺癌样本组织中定量检测 BRMS-1 基因转录本,并分析其与组织学和临床患者预后的关系。使用人乳腺癌细胞系 MDA MB-231 和 MCF-7 对 BRMS-1 的表达进行基因修饰,并在 BRMS-1 修饰后测试生物学反应。还探索了受 BRMS-1 影响的关键候选信号通路。

结果

BRMS1 存在于 MDA MB-231 和 MCF-7 细胞系中。使用抗 BRMS1 转基因,我们在两种细胞中均在 mRNA 和蛋白水平下调 BRMS1 的转录本。与各自的野生型和对照细胞相比,BRMS1 的敲低使两种细胞的细胞生长速度更快,细胞迁移和侵袭速度更快(p<0.05)。阻断磷脂酶 Cγ(PLCγ)对 BRMS-1 诱导的细胞迁移有显著影响。最后,在高级别肿瘤患者(p=0.12)、远处转移患者(p=0.05)和死于乳腺癌的患者(p=0.0037)中观察到 BRMS1 的水平显著降低。此外,BRMS1 水平低的患者总生存期明显缩短(p=0.035)。

结论

BRMS1 在人乳腺癌中异常表达,与疾病进展和患者生存呈负相关。这可能是通过其对乳腺癌细胞侵袭和迁移的影响发生的。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验